Assessment of Liver Morbidity in Breast Cancer Patients Receiving Chemotherapy in Suez Canal University Hospitals | ||
| Afro-Egyptian Journal of Infectious and Endemic Diseases | ||
| Article 2, Volume 9, Issue 1, March 2019, Pages 3-11 PDF (736.02 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/aeji.2019.28431 | ||
| Authors | ||
| Mahmoud M Sheded* 1; Adel A Hassan2; Ehab M Hassanein3 | ||
| 1Infectious and Endemic Hepatology and Gastroenterology Department, Faculty of Medicine, Suez University, Egypt | ||
| 2Infectious Diseases Department, Faculty of Medicine, Suez Canal University, Egypt | ||
| 3Oncology and Nuclear medicine Department, Faculty of Medicine, Suez Canal University, Egypt | ||
| Abstract | ||
| Background and study aim: In Egypt, breast cancer, representing 18.9% of total cancer cases and 35.1% of cancer in women. Potential interactions between the liver and chemotherapy fall into direct chemotherapy-induced hepatotoxicity and Potentiation of preexisting liver disease, especially viral hepatitis.The aim of the study is to assess liver morbidity in breast cancer patients before and 3 months after chemotherapy to assess reactivation of viral hepatitis. Subjects and Methods: This study is prospective study; It included 88 female patients who received chemotherapy for breast cancer. Results: Before chemotherapy 9 patients (10.2%) & 11 patients (12.5%) had elevated ALT & AST respectively which increased after chemotherapy to 32 patients (36.4%) & 29 patients (33%) respectively. Two patients (2.3%) had low serum albumin which increased after chemotherapy to 18 patients (20.5%). None of the patients had elevated S. bilirubin, ascites or jaundice, while after chemotherapy 10 patients (11.4%) had elevated S. bilirubin, 5 patients (5.6%) and 6 patients (6.8%) developed ascites and jaundice respectively. Regarding Child score: None of the patients had Child B/C score before treatment, while after chemotherapy 6 patients (6.8%) developed Child B/C score. Regarding viral hepatitis, 2 of ten patients (20%) who were HBcIgG positive, HBsAg negative with undetectable HBV DNA by PCR developed evidence of HBV reactivation in form of positive PCR for both & reversion of HBsAg for one patient. Conclusion: Chemotherapy for breast cancer carries high risk for hepatotoxicity and reactivation of viral hepatitis. | ||
| Keywords | ||
| Liver; morbidity; Breast; Cancer | ||
|
Statistics Article View: 332 PDF Download: 601 |
||
